Retifanlimab not checked
Incyte Corporation · INCMGA0012 · MGA012
FollowEvery change as it happens, and a Monday email
Trials
5 active
24 in total · 11 in the EU
What this is
- How it works
- Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Receptor-1 Blocking Antibody FDA class
- Tested for
- Solid Tumors
- Main trialPhase 1
- “This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.”In the company’s words, NCT06179160 on ClinicalTrials.gov
- Other names
- INCMGA0012 · MGA012 · INCMGA00012.
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 1 Jan 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials24
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Jan 2027 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | |
| Phase 3Completed | 15 Dec 2023 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | |
| Phase 3Completed | 15 Apr 2024 | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). | |
| Phase 2Completed | 8 Jun 2020 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | |
| Phase 2Completed | 15 Apr 2021 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | |
| Phase 2Completed | 21 Jan 2022 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | |
| Phase 2Terminated | 29 Jan 2024 | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | |
| Phase 2Terminated | 11 Apr 2024 | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. | |
| Phase 2Withdrawn | 20 Apr 2024 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |
| Phase 2Completed | 14 Mar 2025 | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | |
| Phase 2Completed | 29 May 2026 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | |
| Phase 1/2Terminated | 17 Dec 2021 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | |
| Phase 1/2Completed | 25 Aug 2025 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | |
| Phase 1/2Terminated | 29 Jul 2026 | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors | |
| Phase 1Completed | 14 Dec 2021 | A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | |
| Phase 1Completed | 21 Nov 2022 | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 22 Jan 2024 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | |
| Phase 1Completed | 22 May 2024 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | |
| Phase 1Terminated | 19 Sep 2024 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | |
| Phase 1Terminated | 10 Sep 2025 | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies | |
| Phase 2Authorised | not given | PERELI - A phase 2, open label study of PEmigatinib and REtifanlimab in advanced dedifferentiated Liposarcoma | |
| Phase 2Authorised | not given | Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study | |
| Phase 2Authorised | not given | TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SARCOMAS | |
| Phase 2Authorised | not given | Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026